Vapendavir not checked

Altesa Biosciences, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
4 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Rhinovirus Infection
Main trialPhase 2
“Compare the safety and efficacy of two different oral vapendavir doses with placebo in order to determine the appropriate dose of vapendavir to reduce the severity and/or duration of respiratory symptoms associated with RV infections in patients with COPD.”In the company’s words, NCT07610395 on ClinicalTrials.gov
Other names
Vapendaivr

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 15 Nov 2027 Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD
Phase 2Completed 30 Mar 2025 RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection
Phase 1/2Completed 23 Mar 2025 A Study to Evaluate Metabolism, Excretion, and Mass Balance of [14C]Vapendavir
Phase 1Completed 12 Dec 2023 Phase 1 Study Into Pharmacokinetics and Food Effect of Vapendavir in Healthy Participants and Participants With COPD
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Vapendavir

Following is part of Solo: you see every change to Vapendavir the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in